AXS-07 is indicated for the acute treatment of Migraine... Sep 16
Axsome Therapeutics, today announced positive results from the open-label Phase 2 COMET-SI trial of AXS-05 in patients with major depressive disorder (MDD) ... Dec 08
-Advertisements-